Scar Therapeutics - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for scar therapeutics including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Overview of the drug development pipeline for scar therapeutics

It has been observed that scars are the changes in the physical architecture of the skin. A scar occurs on the skin due to damage in the deeper layer of the skin, the dermis. Scars can also occur due to the healing process of skin tissues, and the severity of the scar depends upon the nature of the wound damage. In dermatology, a scar is the area of tissue that replaces the normal skin after an injury. The skin is in direct contact with the environment, and there are high chances of developing sensations and irritations. However, the appearance of scars differs from person to person, depending on the skin type, the location affected, and the type of injury. The different types of scars namely are keloid scars, hypertrophic scars, contracture scars, and acne scars. The most efficient approach for the treatment of scar tissue is considered to be monotherapy.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for the treatment of keloid scars. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Pipeline analysis report on drug development for scar therapeutics: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of different types of scars. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are

• Adisave
• BirchBioMed
• Bonti
• OliX Pharmaceuticals
• Pharmaxis

Therapeutic assessment of the drug development pipeline for scar therapeutics by route of administration

• Intradermal
• Topical
• Intradermal and topical
• Intramuscular
• Oral
• Parenteral
• Subcutaneous
• Subcutaneous and intradermal
• Unknown

The intradermal route of administration (ROA) involves the administration of the drug into the dermis, just below the epidermis with the use of injection, which will have a more direct effect on the target cells. In the topical technique, the drug molecules are applied to a particular place on or in the body

Therapeutic assessment of the drug development pipeline for scar therapeutics by therapy

• Monotherapy
• Unspecified

According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for treatment of scars are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for scar therapeutics?
• What are the companies that are currently involved in the development of drug molecules for scar therapeutics?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.